Announcement on the Resolution of the 10th Board of Directors of the 10th Session
Release time:
2020-08-05
证券代码:600668 证券简称:尖峰集团 编号:临2019-008
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
十届10次董事会决议公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
一、董事会会议召开情况
(一)本次董事会会议的召集、召开符合有关法律、法规及公司《章程》的相关规定。
(二)2019年4月15日,公司以传真、电子邮件及专人送达的方式发出了本次董事会会议通知。
(三)2019年4月26日,本次董事会会议在浙江省金华市尖峰大厦三楼会议室以现场表决的方式召开。
(四)公司现有九名董事,全体董事出席了会议,其中:八名董事亲自参加了会议,杜自弘董事委托董事长蒋晓萌先生代为出席会议并表决。
(五)本次董事会由董事长蒋晓萌主持,公司监事和高级管理人员列席会议。
二、董事会会议审议情况
1、通过了2018年度总经理业务报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
2、通过了2018年度财务决算报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
本报告需提交股东大会审议
3、通过了2018年度利润分配预案
董事会审议并通过了该预案。
公司2018年度拟进行现金分配,以2018年末股本344,083,828股为基数,每10股派发现金红利3.0元(含税),向股权登记日登记在册的全体股东派发现金股利总额为103,225,148.40元(含税)。2018年度不进行公积金转增股本。
表决结果:同意9票、反对0票、弃权0票。
本预案将提交股东大会审议。
详见《关于2018年度利润分配预案的公告》(临2019-015)。
4、通过了聘请公司2019年度审计机构的议案
董事会审议并通过了该议案。同意继续聘请天健会计师事务所(特殊普通合伙)为公司2019年度财务及内部控制审计机构。
表决结果:同意9票、反对0票、弃权0票。
该议案将提交股东大会审议。
5、通过了为控股子公司提供担保的议案
董事会审议并通过了该议案。
对控股子公司的融资及担保,设定如下额度:
|
被担保单位 |
额度(万元) |
|
浙江尖峰药业有限公司 |
30000 |
|
上海北卡医药技术有限公司及其全资子公司 |
20000 |
|
贵州黄平谷陇铭川水泥有限公司 |
30000 |
|
浙江尖峰国际贸易有限公司 |
8000 |
|
合计 |
88000 |
同意上海北卡根据实际经营情况与其下属各全资子公司共同使用上述额度。
2、尖峰国贸是大连商品交易所的指定交割仓库,根据大连商品交易所的要求,需要本公司提供保函,对所存放的期货货物提供担保。另外,为了拓展业务,尖峰国贸目前正在申请郑州商品交易所以及上海期货交易所的交割仓库资质,也需要本公司为其提供担保。为了尖峰国贸顺利开展期货交割仓库业务,拟同意为尖峰国贸出具保函,对存放在尖峰国贸的期货货物提供担保。
在设定额度内的金融机构借款及担保事宜均授权本公司董事长决定执行。
表决结果:同意9票、反对0票、弃权0票。
详见《关于为控股子公司提供担保的公告》(临2019-010)。
本议案需提交股东大会审议。
6、通过了公司会计政策变更的议案
董事会审议并通过了该议案。
表决结果:同意9票、反对0票、弃权0票。
详见《关于公司会计政策变更的公告》(临2019-018)。
7、通过了2018年年度报告及其摘要
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
2018年度报告全文及摘要详见上海证券交易所网站(www.sse.com.cn)。
该报告需提交股东大会审议。
8、通过了2019年第一季度报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
2019年第一季度报告详见上海证券交易所网站(www.sse.com.cn)。
9、关于公司2019年度日常关联交易的议案
董事会审议并通过了该议案。
表决结果:同意6票、反对0票、弃权0票。关联董事蒋晓萌、杜自弘、虞建红回避了该议案的表决。
详见《关于公司2019年度日常关联交易的公告》(临2019-011)。
10、通过了授权董事长利用自有资金进行委托理财的议案
董事会审议并通过了该议案。授权董事长行使不超过人民币5亿元的委托理财的决策权,在该额度内资金可以滚动使用,但任一时点存续的委托理财余额合计不得超过5亿元。每笔委托理财的期限不得超过12个月。授权期限自公司本次董事会审议通过之日起3年内有效。
表决结果:同意9票、反对0票、弃权0票。
详见《关于授权公司董事长利用自有资金进行委托理财的公告》(临2019-012)。
11、通过了召开2018年度股东大会的议案
董事会审议并通过了该议案。董事会决定于2019年5月24日在浙江省金华市婺江东路88号尖峰大厦召开2018年度股东大会,并提供网络表决方式。
表决结果:同意9票、反对0票、弃权0票
详见《关于召开2018年度股东大会的通知》(临2019-017)。
12、通过了公司《章程》修订案
董事会审议并通过了该修订案。
表决结果:同意9票、反对0票、弃权0票。
详见关于修订公司《章程》的公告(临2019-014)。
该议案需提交股东大会审议。
13、通过了公司新修订的《股东大会议事规则》
董事会审议并通过了该议案。
表决结果:同意9票、反对0票、弃权0票。
《股东大会议事规则》详见上海证券交易所网站(www.sse.com.cn)。
该议案需提交股东大会审议。
14、通过了公司新修订的《董事会议事规则》
董事会审议并通过了该议案。
表决结果:同意9票、反对0票、弃权0票。
《董事会议事规则》详见上海证券交易所网站(www.sse.com.cn)。
该议案需提交股东大会审议。
15、通过了尖峰药业增资的关联交易议案
董事会审议并通过了该议案。
表决结果:同意7票、反对0票、弃权0票。关联董事蒋晓萌、刘波回避了该议案的表决。
详见《关于尖峰药业增资的关联交易公告》(临2019-013)。
16、通过了安徽众望增资和二期技改项目的议案
董事会审议并通过了该议案。
本公司控股子公司浙江尖峰药业有限公司的控股子公司上海北卡医药技术有限公司(以下简称:上海北卡)拟出资6000万元对其全资子公司安徽众望制药有限公司(以下简称:安徽众望)进行增资。增资完成后,安徽众望注册资本由原来的4000万元增加至10000万元,上海北卡仍持有100%股权。
安徽众望拟实施二期技改项目,项目总投资17500万元。具体建设内容为:生产车间三、生产车间五、生产车间六、办公楼、研发质检楼、综合仓库一、储罐区(含泵区);新增建设用地约82亩,并对现有二车间设备设施进行局部技改。
表决结果:同意9票、反对0票、弃权0票。
17、通过了2018年度内部控制评价报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
18、通过了战略规划纲要(2019-2023)
董事会审议并通过了该议案。
表决结果:同意9票、反对0票、弃权0票。
《战略规划纲要(2019-2023)》详见上海证券交易所网站(www.sse.com.cn)。
该议案需提交股东大会审议。
19、通过了2018年度《中长期激励基金计提方案》
董事会审议并通过了该议案。根据公司《中长期激励管理办法》的规定,2018年度提取中长期激励基金3475.03万元。
表决结果:同意9票、反对0票、弃权0票。
20、通过了董事会审计委员会2018年度履职报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票
21、通过了独立董事2018年度述职报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票
独立董事将向股东大会报告。
22、通过了2018年度董事会工作报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
该报告将提交股东大会审议。
公司独立董事的其他独立意见:
此外,公司独立董事对上述4(关于聘请公司2019年度审计机构的议案)、5(关于为控股子公司提供担保的议案)、6(关于公司会计政策变更的议案)、9(关于公司2019年度日常关联交易的议案)、10(关于授权董事长利用自有资金进行委托理财的议案)、15(关于尖峰药业增资的关联交易议案)、19(关于2018年度《中长期激励基金计提方案》)七项决议都发表了同意的独立意见,认为:上述董事会决议的形成符合《公司法》、公司《章程》等有关规定,没有损害中小股东的利益。
三、相关附件
1、公司第十届董事会第10次会议决议
2、公司独立董事对上述相关事项的独立董事意见
特此公告
浙江尖峰集团股份有限公司
董事会
二〇一九年四月三十日
More information
Jingmai Airport Test Flight Successfully Runway Cement Spike Manufacturing
On April 7, a Boeing 737-700 aircraft of China Eastern Airlines Yunnan took off from Kunming. After completing two flight test subjects, it landed safely at Lancang Jingmai Airport. This not only marked the basic completion of the airport flight area, The official start of the test flight also marked that the "Peak" brand airport runway cement passed the first "final exam". Lancang Jingmai Airport is a major project with milestone significance in the history of Pu'er transportation construction. Since then, an air corridor connecting southwest Yunnan and Southeast Asia has been added between Kunming and Pu'er, which will greatly promote the development and utilization of tourism resources in Lancang, Menglian and Ximeng "Pu'er Green Triangle" area, and promote the sustainable development of local economy and society; it is of great significance to strengthen the city's national defense construction, maintain border stability, promote national unity, improve emergency rescue capabilities, and promote Pu'er's integration into the country's "Belt and Road" construction. Since the start of the construction of the airport, Yunnan Jianfeng has been paying close attention to it, organizing technical research and repeated tests, and finally produced high-quality airport runway special cement, and with excellent product quality, superior product performance and high-quality service, it has become a runway for Lancang Airport. Cement manufacturer. This not only fills the gap of "peak" airport special cement, but also is of great significance to promote the "peak" brand and improve the market influence of enterprises. It is understood that Jingmai Airport is initially confirmed to be officially opened to traffic at the end of May. (Li Liangping)
2020
07-31
Jianfeng Pharmaceutical Artificial Niuhuang Project Starts
News from this newspaper Jianfeng Pharmaceutical artificial bezoar technical transformation project recently started construction in Qiubin Factory. Artificial bezoar has the effect of clearing away heat and detoxification, resolving phlegm, and is commonly used in Chinese and Western medicines such as colds, clearing away heat and detoxification. As the vast majority of artificial bezoar-related preparations are national essential drugs, with the further implementation of the medical reform policy, the downstream industry of artificial bezoar will enter a new round of business cycle. Jianfeng Pharmaceutical has many years of experience in artificial bezoar production. The technological transformation project will use the existing workshop structure, public works and operators of Qiubin Factory to achieve an annual production capacity of 100 tons of artificial bezoar by adding production equipment such as double cone rotary vacuum drying, horizontal ball mill pulverizer unit, hopper and hoist, closed screening system, and upgrading some public systems. According to the project implementation plan, the project will complete the civil engineering in May. Complete the commissioning, testing and verification of equipment and facilities in July, with trial production conditions; Strive to complete the on-site inspection of GMP certification before the end of December. At present, the factory buildings in Qiubin are vacated and the site is cleaned up. It is understood that the production of natural bezoar is very small, the price is extremely high, and the market rarely provides it. As a biochemical API, artificial bezoar has fewer manufacturers. In the past, due to relatively loose supervision, the testing methods of raw materials and finished products are relatively simple, the quality control indicators are not perfect, and the quality of products on the market is uneven. It is imperative to improve the quality standards. To this end, the State Food and Drug Administration issued the "Biochemical Drug GMP Quality Management Practice (Draft for Comment)" at the end of 2016, which was implemented in March 2017. spike medicine
2020
07-31
Recently, Jianfeng Health has been awarded a number of plaques and certificates by the Department of Science and Technology of Zhejiang Province, the people's Government of Jinhua City, and the Science and Technology Bureau of Jinhua City. They are "Zhejiang Science and Technology small and medium-sized Enterprises", "Jinhua High-tech Enterprises", "Jinhua Agricultural Science and Technology Enterprises", "Jinhua Agricultural Science and Technology Research and Development Center" and so on. According to the relevant requirements, Zhejiang science and technology-based small and medium-sized enterprises must be small and medium-sized enterprises with independent intellectual property rights, proprietary technology or advanced knowledge, engaged in the research, development, production, sales and service of high-tech and its products, and the proportion of enterprises engaged in scientific and technological research and development personnel accounting for no less than 10% of the total number of employees in that year. Since its establishment, Jianfeng Health has attached great importance to the training of scientific and technological personnel, paid attention to the application of its own intellectual property rights, paid attention to product research and development and the protection of intellectual property rights, promoted the application of intellectual property rights, and encouraged employees to invent and create. By the end of 2016, a total of 8 invention patents and 5 appearance patents had been applied, and 1 invention patent and 5 appearance patents had been obtained. High-tech enterprises in Jinhua City must meet the requirements of the ''High-tech Fields Supported by the State, ''and continue to carry out research and development and technological achievements transformation. Their main products (services) have independent intellectual property rights (authorized, registered or accepted). There are certain requirements for the proportion of R & D personnel, the proportion of R & D funds and the income of high-tech products. The acquisition of high-tech enterprises in Jinhua City has laid the foundation for the further declaration of national high-tech enterprises in the future. In the identification of agricultural science and technology enterprises in Jinhua City, the field of peak health technology belongs to the deep processing technology and equipment of agricultural products, Chinese herbal pieces and plant extracts.
2020
07-31
Jingmai Airport Test Flight Successfully Runway Cement Spike Manufacturing
On April 7, a Boeing 737-700 aircraft of China Eastern Airlines Yunnan took off from Kunming. After completing two flight test subjects, it landed safely at Lancang Jingmai Airport. This not only marked the basic completion of the airport flight area, The official start of the test flight also marked that the "Peak" brand airport runway cement passed the first "final exam". Lancang Jingmai Airport is a major project with milestone significance in the history of Pu'er transportation construction. Since then, an air corridor connecting southwest Yunnan and Southeast Asia has been added between Kunming and Pu'er, which will greatly promote the development and utilization of tourism resources in Lancang, Menglian and Ximeng "Pu'er Green Triangle" area, and promote the sustainable development of local economy and society; it is of great significance to strengthen the city's national defense construction, maintain border stability, promote national unity, improve emergency rescue capabilities, and promote Pu'er's integration into the country's "Belt and Road" construction. Since the start of the construction of the airport, Yunnan Jianfeng has been paying close attention to it, organizing technical research and repeated tests, and finally produced high-quality airport runway special cement, and with excellent product quality, superior product performance and high-quality service, it has become a runway for Lancang Airport. Cement manufacturer. This not only fills the gap of "peak" airport special cement, but also is of great significance to promote the "peak" brand and improve the market influence of enterprises. It is understood that Jingmai Airport is initially confirmed to be officially opened to traffic at the end of May. (Li Liangping)
2020
07-30
Peak Pharmaceutical was rated as a national intellectual property advantage enterprises
The score ranked first among Jinhua participating enterprises. A few days ago, Peak Pharmaceutical Company was rated as a national intellectual property advantage enterprise. The selection of national intellectual property advantage enterprises is organized by the State Intellectual Property Office. The purpose is to accelerate the formation of a group of Chinese intellectual property leading enterprises with independent intellectual property rights, well-known brands and international competitive advantages, and achieve the development goal of strong intellectual property enterprises. Since Jianfeng Pharmaceutical introduced the GB-T29490-2013 "Enterprise Intellectual Property Management Standard" in 2013, it has been rated as a patent demonstration enterprise in Zhejiang Province in 2013. In 2014, the "Jianfeng" trademark obtained a famous trademark in Zhejiang Province, and the first edition of the "Intellectual Property Manual" was compiled and implemented in 2015. In 2016, it passed the third-party certification of the GB-T29490-2013 "Enterprise Intellectual Property Management Standard". The "Jianfeng" trademark was rated as a well-known trademark by the State Administration of China. In the application and selection of national knowledge by superior enterprises, 52 enterprises in Zhejiang Province won this honor, ranking second in the country in number; Jianfeng Pharmaceutical ranked first among Jinhua participating enterprises. (Zhang Mingyin)
2020
07-31
Group Party Committee to determine the annual work plan
The party Committee of the group company has determined its work ideas and work plan for 2017 a few days ago, and relevant work has been arranged below. In view of the current new political and economic situation and the task of enterprise transformation and development, the general requirements of the Party Committee of the Group Company for 2017 are: to thoroughly study and implement the spirit of the Sixth Plenary Session of the 18th CPC Central Committee and the series of important speeches by General Secretary Xi Jinping, the spirit of the Seventh Party Congress of Jinhua City, to closely revolve around the center of enterprise production, operation and reform and development, and to adhere to scientific development and cross-regional development as the first priority, in order to continue to carry out the study and education of "five stars striving for innovation" and "two learning and one doing", we should highlight the main line of comprehensively and strictly administering the party according to the rules, firmly establish the political consciousness, overall situation consciousness, core consciousness and alignment consciousness of the majority of Party members and cadres, strengthen and improve the party building work in enterprises in the spirit of reform, and strive to improve the scientific, standardized and institutionalized level of Party building work in enterprises, in order to promote the scientific development of the group company, leapfrog development and harmonious development, it provides a strong political, ideological and organizational guarantee. The working idea of the Party Committee of the Group Company in 2017 is to focus on "one center", adhere to "one concept", highlight "three key points" and do a good job in "three constructions". That is: centering on the "one center" of enterprise production, operation and reform and development, we should strive to strengthen the "one concept" of "the organic unity of the party's leadership and the improvement of corporate governance"; to "thoroughly implement the main responsibility of the party committee; continue to carry out the study and education of" two learning and one doing "; and improve the system of party building work" as the "three key points", and focus on "team building and team building
2020
07-31